Meet the Mobia Medical Leadership Team

Richard serves as President and CEO of Mobia Medical, bringing over 20 years of global leadership experience in the healthcare industry. He has deep experience in commercialization, portfolio strategy, and cross-functional senior leadership. Mr. Foust previously served as Chief Commercial Officer at Velano Vascular (acquired by Beckton Dickinson) and held multiple senior roles at Abbott (NYSE: ABT), including as a Director in the Global Endovascular Business Unit and as Marketing Director of the EMEA Coronary Business. Earlier in his career, he held leadership roles at Analyte Healthcare and Guidant (NYSE: GDT). He holds a BS in Applied Physics from Emory University and an MSME in Bioengineering from Georgia Institute of Technology.

Steffanie is an accomplished HR leader with over 20 years of experience in talent management, employee development, and organizational design. Most recently, Steffanie led the HR Business Partner, Learning and Development, and HR Operations functions at Silk Road Medical, where her efforts were pivotal in the company’s growth and successful acquisition by Boston Scientific. Prior to this, she held key HR leadership roles at Endologix and Honeywell Aerospace, where she developed impactful programs to drive talent engagement, leadership development, and operational excellence. She holds a Master’s Degree in Business Administration and a Bachelor’s in Psychology from California State University, Long Beach.

Bunker joined Mobia Medical with 15 years of experience in finance and operations roles in various industries. He has worked with Mobia since 2011 in various financial roles before becoming CFO in 2020. Prior to joining Mobia, Mr. Curnes worked as the CFO for HEMCO Development. Previously, he worked at the Boston Consulting Group on a variety of projects across the healthcare, energy, and retail consumer sectors. Bunker holds a BS in Mechanical Engineering from the University of Notre Dame and an MBA from the Fuqua School of Business at Duke University.

Jordan co-founded Mobia Medical and has helped shape its business strategy and commercialization since the company’s founding in 2007. His experience includes management consulting at Huron Consulting Group with a focus on large healthcare corporations. Mr. Curnes remains active in investing and entrepreneurial mentorship. He holds a BBA in Finance from the University of Notre Dame and an MBA from the Fuqua School of Business at Duke University.

Doug has over 33 years of successful sales, marketing, new program development and executive management experience in the medical device industry encompassing minimally invasive technologies, oncology and cardiology. He most recently served as National Director, Hybrid Therapies at AtriCure post acquisition of SentreHEART. Prior to acquisition, Doug was VP of Sales at SentreHEART for 11 years. Previously, he served as VP of WW Sales and Marketing for Cardica Inc. Between acquisitions, he consulted with CardioVations, a division of Johnson and Johnson/Ethicon and Bard Biopsy System a division of C.R. Bard. He previously served as the VP of Sales at Artemis Medical, Inc., Sales Director at Heartport, Inc., and with Guidant Corp. in sales and sales management. He also served at Davol (C.R. Bard) in a variety of sales and sales management positions. Doug was instrumental in the integration of the Guidant Vascular Interventional sales forces from the Eli Lilly Corp. and development of the broad Heartport franchise. Doug received his B.S. in Engineering from Purdue University.

Navzer has been instrumental in developing the Paired VNS™ technology platform. Navzer’s research in neuroplasticity and VNS laid the foundation of our stroke therapy. He has been the recipient of several grants from the NIH related to the VNS therapy and his research has been published in leading peer-reviewed journals including Nature, and The Lancet. Navzer completed his medical training in India and then earned a PhD in Neuroscience from the University of Texas at Dallas.

Chase Leavitt has served as our General Counsel and Corporate Secretary since February 2026. Previously, Mr. Leavitt served as General Counsel and Corporate Secretary of Oncternal Therapeutics, Inc., a publicly traded biotechnology company, from April 2021 to June 2025. Mr. Leavitt also served as General Counsel and Corporate Secretary of Lineage Cell Therapeutics, Inc. (NYSE: LCTX), a publicly traded biotechnology company, from May 2019 to April 2021. Mr. Leavitt previously served as Vice President of Legal Affairs of Tang Capital Management, LLC, a life sciences-focused investment company, and its affiliate Odonate Therapeutics, Inc., a publicly traded pharmaceutical company, from June 2018 to May 2019. Mr. Leavitt had escalating roles at Switch, Inc., a technology company, from 2014 to 2018, most recently as Deputy General Counsel through the company’s initial public offering. Mr. Leavitt was a corporate attorney at Latham & Watkins LLP from 2007 to 2014. Mr. Leavitt received a B.S. in Business Administration and a J.D. from the University of Southern California and is admitted to practice law in the States of California, Washington, and Texas.

Swaril is a strategic growth leader with deep expertise in building and scaling transformative medical technologies through early-stage innovation, M&A, and go-to-market execution. Previously, as Vice President of Business Development at Axonics, she led M&A and strategic initiatives, including the company’s $3.7B acquisition by Boston Scientific. Prior to joining Axonics, Swaril drove early-stage innovation at Edwards Lifesciences as a member of the Advanced Technology group, and at Stanford University as a Biodesign Innovation Fellow. In these roles, she partnered with engineers and physicians to identify and address unmet clinical needs in cardiology and otolaryngology. She remains actively involved with Stanford Biodesign, as Assistant Director of its Global Faculty Training program, which equips international leaders to support needs-driven healthcare innovation in their home countries. Swaril began her career at Boston Consulting Group, supporting strategic transformations and business integrations for leading healthcare clients. She holds an M.S. in Bioengineering from Stanford University and a B.S. in Biomedical Engineering from the University of California, Irvine.

Prashant has over 25 years of global experience in building and leading teams to deliver novel therapies in the neurostimulation, neurovascular and cardiac fields. He previously worked at Boston Scientific, Mainstay Medical, CSF Therapeutics and CVRx. His experience spans management of research and development, clinical and regulatory operations, manufacturing and distribution, and building intellectual property portfolios. Prashant has a BS in Electronics Engineering from the Maharaja Sayajirao University in India, and a MS in Electrical Engineering and Applied Physics from Case Western Reserve University. He is the inventor on over 85 patents and patent applications.